PAG
EW icon

Private Advisor Group’s Edwards Lifesciences EW Stock Holding History

Private Advisor Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-800
Closed -$304 – 2312
2023
Q3 		$304 Buy
+800
New +$64.3K ﹤0.01% 2282

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Private Advisor Group's EW Position: Q1 2026 in Review

Private Advisor Group reduced its Edwards Lifesciences (EW) stake by 3% in Q1 2026, selling an estimated $55.2K and leaving 21,610 shares worth $1.73M. The position accounts for 0.01% of the portfolio, ranked #1117.

Private Advisor Group first reported a position in EW in Q2 2014 and has held it in 45 quarters since. The position peaked at $4.81M in Q3 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Private Advisor Group held 21,610 shares of Edwards Lifesciences worth $1.73M as of Q1 2026.
  • Private Advisor Group sold 670 Edwards Lifesciences shares in Q1 2026, an estimated $55.2K.
  • Edwards Lifesciences made up 0.01% of Private Advisor Group's portfolio in Q1 2026, its #1117 holding.
  • Private Advisor Group first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 45 quarters since.
  • Private Advisor Group's Edwards Lifesciences position peaked at $4.81M in Q3 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.